Form 4: Director Acquires Anika Therapeutics Stock

Anika Therapeutics Director John B. Henneman III has acquired 5,000 shares of common stock.

Summary

• John B. Henneman III, a Director at Anika Therapeutics, Inc., purchased 5,000 shares of common stock on May 1, 2026.
• The purchase was made at a weighted average price of $14.6639 per share, with individual transactions ranging from $14.595 to $14.75.
• Following this transaction, Mr. Henneman beneficially owns 54,871 shares of Anika Therapeutics common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as a director's personal investment in the company's stock often indicates confidence in its future performance.

Positives

• Director's confidence in the company is demonstrated through a significant stock purchase.
• The acquisition of 5,000 shares indicates a belief in the future value of Anika Therapeutics.

Future Outlook

No specific forward-looking statements or guidance are present in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by directors, can signal confidence in a company's prospects within the biotechnology and medical device sector.

Stakeholder Impact

• Shareholders may view this purchase positively, interpreting it as a sign of management's confidence in the company's value and future prospects.

Key Dates

Recommendation

While an insider purchase is a positive indicator, this Form 4 filing solely reports a transaction and does not contain operational or financial results that would warrant a stronger recommendation. It suggests continued confidence but not necessarily immediate upside.

Keywords

Anika Therapeutics, SEC Form 4, Insider Trading, Stock Purchase, Director Acquisition, Beneficial Ownership